The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Dyspnea

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Dyspnea

 

Psychiatry related information on Dyspnea

 

High impact information on Dyspnea

  • The perception of dyspnea was scored on the Borg scale during breathing through inspiratory resistances ranging from 0 to 30.9 cm of water per liter per second [11].
  • During the first week after discharge, patients receiving prednisone reported significantly lower mean (+/- SD) daily symptom scores for shortness of breath (1.4 +/- 0.4 vs. 2.5 +/- 0.4, P less than 0.01) and less frequent use of an inhaled bronchodilator (5.2 +/- 0.5 vs. 6.9 +/- 0.2 puffs per day, P less than 0.05) than patients receiving placebo [12].
  • Niacin-treated rats showed delayed and reduced dyspnea [13].
  • On the summit AMS was less common in climbers receiving acetazolamide, and they experienced less headache, nausea, drowsiness, shortness of breath, and dizziness and a greater sense of satisfaction and psychological well-being [14].
  • However, there were no significant differences between the placebo and aminophylline groups in any of the spirometric measurements or the dyspnea indices (p greater than 0.5 in all five analyses) [15].
 

Chemical compound and disease context of Dyspnea

  • Borg Dyspnea Scores and Dyspnea-Fatigue Ratings improved in the epoprostenol group [16].
  • Significant improvements in FEV1 and FVC measured before and after metaproterenol treatment and in dyspnea occurred over time in both treatment groups (p less than 0.05 for all measurements) [15].
  • In selected patients, chronic afterload reduction with oral hydralazine may result in increased cardiac reserve, decreased pulmonary congestion or decreased myocardial oxygen demands, thereby improving or abolishing resting or exertional dyspnea or angina [17].
  • Symptoms were common, regardless of estrogen treatment (abdominal pain 60%, shortness of breath 40%, or both 35%) [18].
  • Of 19 consecutive smokers of cocaine, "freebase" cocaine users, admitted to a chemical dependence program, 12 (63%) had respiratory symptoms and ten (58%) noted dyspnea [19].
 

Biological context of Dyspnea

 

Anatomical context of Dyspnea

  • A 72-year-old woman was initially seen with increasing dyspnea and a new murmur occurring six years after mitral valve replacement with a glutaraldehyde-stabilized porcine xenograft [25].
  • We conclude that epinephrine appears to be an important factor in the regulation of the bronchial smooth muscle tone in patients with early morning dyspnea [26].
  • The role of endogenous hydrocortisone in the regulation of lymphocyte activity was assayed in patients with asthma (patients with chronic nonspecific lung disease, characterized by attacks of dyspnea, alternating with symptom-free periods) and healthy control subjects [27].
  • In patients with hypertrophic cardiomyopathy, clinical symptoms such as exertional dyspnea, angina and collapse are considered to be rather the consequence of diastolic than of systolic dysfunction of the left ventricle [28].
  • Exacerbations of COPD, which include combinations of dyspnea, cough, wheezing, increased sputum production (and a change in its color to green or yellow), are common [29].
 

Gene context of Dyspnea

 

Analytical, diagnostic and therapeutic context of Dyspnea

References

  1. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. Murciano, D., Auclair, M.H., Pariente, R., Aubier, M. N. Engl. J. Med. (1989) [Pubmed]
  2. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. Wright, D.G., Robichaud, K.J., Pizzo, P.A., Deisseroth, A.B. N. Engl. J. Med. (1981) [Pubmed]
  3. Fatal pulmonary reaction from low doses of bleomycin. An idiosyncratic tissue response. Iacovino, J.R., Leitner, J., Abbas, A.K., Lokich, J.J., Snider, G.L. JAMA (1976) [Pubmed]
  4. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ries, A.L., Kaplan, R.M., Limberg, T.M., Prewitt, L.M. Ann. Intern. Med. (1995) [Pubmed]
  5. Large, compressive goiters treated with radioiodine. Huysmans, D.A., Hermus, A.R., Corstens, F.H., Barentsz, J.O., Kloppenborg, P.W. Ann. Intern. Med. (1994) [Pubmed]
  6. Panic disorder: a treatment update. Burrows, G.D., Norman, T.R., Judd, F.K. The Journal of clinical psychiatry. (1991) [Pubmed]
  7. Progressive massive fibrosis of the lung secondary to intravenous injection of talc. A pathologic and mineralogic analysis. Crouch, E., Churg, A. Am. J. Clin. Pathol. (1983) [Pubmed]
  8. The goitrogenic effect of 4,4'-oxydianiline in rats and mice. Hayden, D.W., Wade, G.G., Handler, A.H. Vet. Pathol. (1978) [Pubmed]
  9. Stroke and pulmonary thromboembolism after a long flight. Belvís, R., Masjuan, J., García-Barragán, N., Cocho, D., Martí-Fàbregas, J., Santamaría, A., Leta, R.G., Martínez-Castrillo, J.C., Fernández-Ruiz, L.C., Gilo, F., Martí-Vilalta, J.L. Eur. J. Neurol. (2005) [Pubmed]
  10. Consistencies between recalled panic and lactate-induced panic. Goetz, R.R., Klein, D.F., Gorman, J.M. Anxiety (1994) [Pubmed]
  11. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. Kikuchi, Y., Okabe, S., Tamura, G., Hida, W., Homma, M., Shirato, K., Takishima, T. N. Engl. J. Med. (1994) [Pubmed]
  12. Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma. Chapman, K.R., Verbeek, P.R., White, J.G., Rebuck, A.S. N. Engl. J. Med. (1991) [Pubmed]
  13. Niacin Reduces Paraquat Toxicity in Rats. Brown, O.R., Heitkamp, M., Song, C.S. Science (1981) [Pubmed]
  14. Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. Larson, E.B., Roach, R.C., Schoene, R.B., Hornbein, T.F. JAMA (1982) [Pubmed]
  15. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. Rice, K.L., Leatherman, J.W., Duane, P.G., Snyder, L.S., Harmon, K.R., Abel, J., Niewoehner, D.E. Ann. Intern. Med. (1987) [Pubmed]
  16. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Badesch, D.B., Tapson, V.F., McGoon, M.D., Brundage, B.H., Rubin, L.J., Wigley, F.M., Rich, S., Barst, R.J., Barrett, P.S., Kral, K.M., Jöbsis, M.M., Loyd, J.E., Murali, S., Frost, A., Girgis, R., Bourge, R.C., Ralph, D.D., Elliott, C.G., Hill, N.S., Langleben, D., Schilz, R.J., McLaughlin, V.V., Robbins, I.M., Groves, B.M., Shapiro, S., Medsger, T.A. Ann. Intern. Med. (2000) [Pubmed]
  17. Rest and exercise hemodynamic effects of oral hydralazine in patients with coronary artery disease and left ventricular dysfunction. Hindman, M.C., Slosky, D.A., Peter, R.H., Newman, G.E., Jones, R.H., Wallace, A.G. Circulation (1980) [Pubmed]
  18. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Sherstha, R., McKinley, C., Russ, P., Scherzinger, A., Bronner, T., Showalter, R., Everson, G.T. Hepatology (1997) [Pubmed]
  19. Pulmonary dysfunction in 'freebase' cocaine users. Itkonen, J., Schnoll, S., Glassroth, J. Arch. Intern. Med. (1984) [Pubmed]
  20. Growth of hepatocellular carcinoma into the right atrium. Report of five cases. Kato, Y., Tanaka, N., Kobayashi, K., Ikeda, T., Hattori, N., Nonomura, A. Ann. Intern. Med. (1983) [Pubmed]
  21. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. Ziegler, L.D., Palazzolo, P., Cunningham, J., Janus, M., Itoh, K., Hayakawa, K., Hellstrom, I., Hellstrom, K.E., Nicaise, C., Dennin, R. J. Clin. Oncol. (1992) [Pubmed]
  22. Lung function improvements with once-daily tiotropium in chronic obstructive pulmonary disease. Casaburi, R., Conoscenti, C.S. Am. J. Med. (2004) [Pubmed]
  23. The effect of acetazolamide on ventilation in panic disorder patients. Gorman, J.M., Papp, L.A., Coplan, J., Martinez, J., Liebowitz, M.R., Klein, D.F. The American journal of psychiatry. (1993) [Pubmed]
  24. Pulmonary hemorrhage after intracoronary stent placement. Brown, D.L., MacIsaac, A.I., Topol, E.J. J. Am. Coll. Cardiol. (1994) [Pubmed]
  25. Production of abnormal systolic sounds by vibration of torn leaflet of porcine xenograft. Come, P.C. Arch. Intern. Med. (1983) [Pubmed]
  26. Influence of slow-release terbutaline on the circadian variation of catecholamines, histamine, and lung function in nonallergic patients with partly reversible airflow obstruction. Postma, D.S., Koëter, G.H., Keyzer, J.J., Meurs, H. J. Allergy Clin. Immunol. (1986) [Pubmed]
  27. Sensitivity to hydrocortisone is a relevant factor in the immunoendocrine relationship. I. The cell-mediated immune response in relation to blood levels and in vitro immunosuppressive effects of hydrocortisone in patients with asthma and healthy control subjects. Weller, F.R., Weller, H.H., Kallenberg, C.G., The, T.H., Orie, N.G. J. Allergy Clin. Immunol. (1986) [Pubmed]
  28. Treatment of hypertrophic cardiomyopathy: relation to pathological mechanisms. Kaltenbach, M., Hopf, R. J. Mol. Cell. Cardiol. (1985) [Pubmed]
  29. Do bacteria cause exacerbations of COPD? Hirschmann, J.V. Chest (2000) [Pubmed]
  30. Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Hersh, C.P., Demeo, D.L., Lazarus, R., Celedón, J.C., Raby, B.A., Benditt, J.O., Criner, G., Make, B., Martinez, F.J., Scanlon, P.D., Sciurba, F.C., Utz, J.P., Reilly, J.J., Silverman, E.K. Am. J. Respir. Crit. Care Med. (2006) [Pubmed]
  31. Response of C-reactive protein and serum amyloid A to influenza A infection in older adults. Falsey, A.R., Walsh, E.E., Francis, C.W., Looney, R.J., Kolassa, J.E., Hall, W.J., Abraham, G.N. J. Infect. Dis. (2001) [Pubmed]
  32. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Mahler, D.A., Huang, S., Tabrizi, M., Bell, G.M. Chest (2004) [Pubmed]
  33. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Utz, J.P., Limper, A.H., Kalra, S., Specks, U., Scott, J.P., Vuk-Pavlovic, Z., Schroeder, D.R. Chest (2003) [Pubmed]
  34. Hemostatic studies in patients with carbohydrate-deficient glycoprotein syndrome. Iijima, K., Murakami, F., Nakamura, K., Ikawa, S., Yuasa, I., Motosumi, H., Ohno, K., Takeshita, K. Thromb. Res. (1994) [Pubmed]
  35. Stress-induced left ventricular outflow tract obstruction: a potential cause of dyspnea in the elderly. Henein, M.Y., O'Sullivan, C., Sutton, G.C., Gibson, D.G., Coats, A.J. J. Am. Coll. Cardiol. (1997) [Pubmed]
  36. Does oxygen help dyspnea in patients with cancer? Booth, S., Kelly, M.J., Cox, N.P., Adams, L., Guz, A. Am. J. Respir. Crit. Care Med. (1996) [Pubmed]
  37. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Hajiro, T., Nishimura, K., Tsukino, M., Ikeda, A., Koyama, H., Izumi, T. Am. J. Respir. Crit. Care Med. (1998) [Pubmed]
  38. Longitudinal changes in lung function among asbestos-exposed workers. Schwartz, D.A., Davis, C.S., Merchant, J.A., Bunn, W.B., Galvin, J.R., Van Fossen, D.S., Dayton, C.S., Hunninghake, G.W. Am. J. Respir. Crit. Care Med. (1994) [Pubmed]
  39. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer. Hank, J.A., Albertini, M., Wesly, O.H., Schiller, J.H., Borchert, A., Moore, K., Bechhofer, R., Storer, B., Gan, J., Gambacorti, C. Clin. Cancer Res. (1995) [Pubmed]
 
WikiGenes - Universities